

# Efficacy and safety of sitagliptin when added to insulin diabetes

Diabetes, Obesity and Metabolism

12, 167-177

DOI: [10.1111/j.1463-1326.2009.01173.x](https://doi.org/10.1111/j.1463-1326.2009.01173.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3, 31.	1.1	36
3	Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders, 2010, 10, 7.	0.9	234
5	Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, Volume 3, 31-41.	1.1	17
6	Weight Management in Overweight and Obese Patients with Type 2 Diabetes Mellitus. British Journal of Diabetes and Vascular Disease, 2010, 10, 274-283.	0.6	15
7	Respuesta del Dr. Manuel Delgado GÃ³mez. Avances En DiabetologÃ­a, 2010, 26, 440-444.	0.1	0
8	Sitagliptin. Drugs, 2010, 70, 489-512.	4.9	96
9	Management of Unmet Needs in Type 2 Diabetes Mellitus: The Role of Incretin Agents. Canadian Journal of Diabetes, 2011, 35, 518-527.	0.4	3
10	Sitagliptin/metformin fixed-dose combination: a guide to its use in type 2 diabetes mellitus. Drugs and Therapy Perspectives, 2011, 27, 1-5.	0.3	0
11	Sitagliptin: a review. Expert Opinion on Pharmacotherapy, 2011, 12, 1613-1622.	0.9	35
12	Sitagliptin/Metformin Fixed-Dose Combination. Drugs, 2011, 71, 349-361.	4.9	22
13	Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 2560-2566.	4.3	174
14	Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights Therapeutics, 2011, 3, CMT.S6227.	0.4	1
15	Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration. Diabetes and Metabolism Journal, 2011, 35, 290.	1.8	9
16	Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2011, 6, 543-556.	1.2	0
17	Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism, 2011, 13, 7-18.	2.2	428
18	The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 2011, 13, 169-180.	2.2	64
19	Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes, Obesity and Metabolism, 2011, 13, 268-275.	2.2	54
20	The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2011, 13, 644-652.	2.2	74

#	ARTICLE	IF	CITATIONS
21	Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*. Diabetes, Obesity and Metabolism, 2011, 13, 703-710.	2.2	83
22	Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. Journal of Medical Case Reports, 2011, 5, 117.	0.4	27
25	Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Therapy, 2011, 2, 51-66.	1.2	31
26	Emerging role of insulin with incretin therapies for management of type 2 diabetes. Diabetes Therapy, 2011, 2, 146-161.	1.2	9
27	Type 2 Diabetes. Diabetes Care, 2011, 34, e11-e16.	4.3	9
28	Transitioning From Inpatient to Outpatient Therapy in Patients with In-Hospital Hyperglycemia. Hospital Practice (1995), 2011, 39, 87-95.	0.5	5
29	Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. Expert Opinion on Pharmacotherapy, 2011, 12, 2055-2067.	0.9	1
30	Choosing a Gliptin. Indian Journal of Endocrinology and Metabolism, 2011, 15, 298.	0.2	67
31	Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience. Diabetes Technology and Therapeutics, 2012, 14, 350-364.	2.4	58
32	The Role of Self-Monitoring of Blood Glucose in Glucagon-like Peptide-1-Based Treatment Approaches: A European Expert Recommendation. Journal of Diabetes Science and Technology, 2012, 6, 665-673.	1.3	12
33	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Spectrum, 2012, 25, 154-171.	0.4	28
34	Inhibition of Dipeptidyl Peptidase-4 (DPP-4): A Target to Treat Type 2 Diabetes. Current Enzyme Inhibition, 2012, 7, 205-217.	0.3	5
35	Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocrine Journal, 2012, 59, 1131-1136.	0.7	24
36	Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis. Annals of Pharmacotherapy, 2012, 46, 1453-1469.	0.9	86
37	New avenues for the pharmacological management of type 2 diabetes: An update. Annales D'Endocrinologie, 2012, 73, 459-468.	0.6	5
38	Sitagliptin in the treatment of type 2 diabetes: a meta-analysis. Journal of Evidence-Based Medicine, 2012, 5, 154-165.	0.7	13
39	Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	0.4	3
40	DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes and Metabolism, 2012, 38, 89-101.	1.4	157

#	ARTICLE	IF	CITATIONS
41	Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, $\beta$ -cell function and insulin resistance in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 51-60.	1.1	64
42	Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. <i>European Journal of Internal Medicine</i> , 2012, 23, 132-136.	1.0	15
43	Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. <i>International Journal of Clinical Practice</i> , 2012, 66, 1147-1157.	0.8	14
44	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. <i>Diabetes Care</i> , 2012, 35, 1364-1379.	4.3	3,077
45	Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. <i>Current Medical Research and Opinion</i> , 2012, 28, 513-523.	0.9	153
46	Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. <i>Primary Care Diabetes</i> , 2012, 6, 41-46.	0.9	65
47	Prise en charge de lâ€™hyperglycémie chez le patient diabétique de type 2 : une stratégie centrée sur le patient. <i>Medicine Des Maladies Metaboliques</i> , 2012, 6, III-XXV.	0.1	2
48	Insulin Therapy in Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 119-144.	1.2	28
49	Reevaluating Goals of Insulin Therapy: Perspectives from Large Clinical Trials. <i>Endocrinology and Metabolism Clinics of North America</i> , 2012, 41, 41-56.	1.2	6
50	Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes. <i>Diabetes Therapy</i> , 2012, 3, 11.	1.2	7
51	Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a systematic review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012, 5, 165.	1.1	26
52	Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2012, 55, 1577-1596.	2.9	1,718
53	Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012, 37, 510-524.	0.7	36
54	Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes. <i>International Journal of Clinical Practice</i> , 2012, 66, 465-476.	0.8	43
55	Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 481-492.	2.2	21
56	GLP-1 based therapies: differential effects on fasting and postprandial glucose. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 675-688.	2.2	100
57	Liraglutide: from clinical trials to clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 33-40.	2.2	34
58	Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 795-802.	2.2	72

#	ARTICLE	IF	CITATIONS
59	Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 1061-1072.	2.2	128
60	Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. <i>Diabetes Therapy</i> , 2013, 4, 119-145.	1.2	109
61	Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes. <i>Diabetology International</i> , 2013, 4, 251-256.	0.7	2
62	Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. <i>Diabetology International</i> , 2013, 4, 160-172.	0.7	23
63	Hypoglycemia: Minimizing Its Impact in Type 2 Diabetes. <i>Endocrine Practice</i> , 2013, 19, 526-535.	1.1	32
64	Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. <i>Cardiovascular Diabetology</i> , 2013, 12, 3.	2.7	84
65	Insulin therapy for type 2 diabetes. <i>Endocrine</i> , 2013, 43, 529-534.	1.1	11
66	Complementing Insulin Therapy to Achieve Glycemic Control. <i>Advances in Therapy</i> , 2013, 30, 557-576.	1.3	30
67	Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy. <i>Clinical Drug Investigation</i> , 2013, 33, 707-717.	1.1	47
68	The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. <i>Endocrine Practice</i> , 2013, 19, 1050-1061.	1.1	29
69	Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3875-3881.	4.3	124
70	Intensifying Insulin Therapy: What Options Are Available to Patients with Type 2 Diabetes?. <i>American Journal of Medicine</i> , 2013, 126, S28-S37.	0.6	28
71	American Association of Clinical Endocrinologists™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 1-48.	1.1	132
72	Pharmacoth�rapie du diab�te de type 2. <i>Canadian Journal of Diabetes</i> , 2013, 37, S428-S436.	0.4	1
73	Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes. <i>Diabetes Therapy</i> , 2013, 4, 409-416.	1.2	3
74	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. <i>International Journal of Clinical Practice</i> , 2013, 67, 1267-1282.	0.8	281
75	Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. <i>American Heart Journal</i> , 2013, 166, 983-989.e7.	1.2	116
76	Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes. <i>Diabetes and Metabolism</i> , 2013, 39, 6-15.	1.4	27

#	ARTICLE	IF	CITATIONS
77	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary. <i>Endocrine Practice</i> , 2013, 19, 536-557.	1.1	230
78	Pharmacologic Management of Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, S61-S68.	0.4	115
79	Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, e55-e58.	1.1	90
80	Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 252-257.	2.2	98
81	A review of the efficacy and safety of oral antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 153-175.	1.0	251
82	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (æ—°âž<2âž<ç³—â°¿ç—...æ²»ç—è•ç%©i¹¼šç¬→2éƒ'â†. 2013â¹'â,â°Sâ,Se'â¹è,â¿fèf'â²,ç'ç¼48™.çš,,â¿	0.8	8
83	The Place of GLP-1â€‘Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists. <i>Current Diabetes Reports</i> , 2013, 13, 307-318.	1.7	21
84	Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. <i>Diabetologia</i> , 2013, 56, 696-708.	2.9	334
85	Emerging gliptins for type 2 diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 245-258.	1.0	30
86	Extraâ€‘pancreatic effects of incretinâ€‘based therapies: potential benefit for cardiovascularâ€‘risk management inâ€‘type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2013, 15, 593-606.	2.2	42
87	Reshaping Diabetes Care: The Fundamental Role of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Clinical Practice. <i>Endocrine Practice</i> , 2013, 19, 718-728.	1.1	9
88	Sitagliptin: results from clinical practice. <i>Current Medical Research and Opinion</i> , 2013, 29, 1483-1485.	0.9	2
89	Sitagliptin and Vildagliptin Efficacy on Carbohydrate and Lipid Metabolism in Elderly Patients with Type 2 Diabetes. <i>Romanian Journal of Diabetes Nutrition and Metabolic Diseases</i> , 2013, 20, 55-62.	0.3	0
90	Combination Therapy With DPP-4 Inhibitors and Insulin in Patients With Type 2 Diabetes Mellitus: What Is the Evidence?. <i>Hospital Practice (1995)</i> , 2013, 41, 93-107.	0.5	19
91	Combining Incretin-Based Therapies With Insulin. <i>Diabetes Care</i> , 2013, 36, S226-S232.	4.3	42
92	Self-Monitoring of Blood Glucose in Glucagon-Like Peptide-1-Based Treatment Approaches. <i>Diabetes Spectrum</i> , 2013, 26, 107-111.	0.4	1
93	Linagliptin as add-on therapy to insulin for patients with type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2013, 9, 681.	1.0	14
94	A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 181-189.	0.7	3

#	ARTICLE	IF	CITATIONS
95	Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. <i>European Diabetes Nursing</i> , 2013, 10, 31-36.	0.2	8
96	Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks. <i>Journal of Diabetes Investigation</i> , 2013, 4, 174-181.	1.1	21
97	Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy. <i>Journal of Diabetes Investigation</i> , 2013, 4, 618-625.	1.1	13
98	Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2013, 60, 733-742.	0.7	39
99	Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. <i>Endocrine Journal</i> , 2013, 60, 1207-1214.	0.7	28
100	Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2013, 9, 155.	1.0	135
101	Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. <i>Drug Design, Development and Therapy</i> , 2013, 7, 99.	2.0	15
102	Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. <i>International Journal of General Medicine</i> , 2013, 6, 877.	0.8	65
103	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. <i>Vascular Health and Risk Management</i> , 2013, 9, 273.	1.0	7
104	Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2013, 6, 187.	1.1	75
105	Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study. <i>Vascular Health and Risk Management</i> , 2013, 9, 711.	1.0	9
106	A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. <i>Drug Design, Development and Therapy</i> , 2013, 7, 893.	2.0	16
107	Type 2 Diabetes Treatment Recommendations Update: Appropriate Use of Dipeptidyl Peptidase-4 Inhibitors. <i>Journal of Diabetes &amp; Metabolism</i> , 2014, 05, .	0.2	2
108	Efficacy of Adding Once-Daily Insulin Glulisine in Japanese Type 2 Diabetes Patients Treated with Insulin Glargine and Sitagliptin. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 633-639.	2.4	2
109	The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 787-812.	1.5	59
110	Patients with Type 2 Diabetes Mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin. <i>BMC Research Notes</i> , 2014, 7, 579.	0.6	2
111	Adding of Sitagliptin on Insulin Therapy Effectively and Safely Reduces a Hemoglobin A1c Level and Glucose Fluctuation in Japanese Patients with Type 2 Diabetes. <i>International Scholarly Research Notices</i> , 2014, 2014, 1-6.	0.9	2
112	Individualizing Insulin Therapy in the Management of Type 2 Diabetes. <i>American Journal of Medicine</i> , 2014, 127, S3-S10.	0.6	18

#	ARTICLE	IF	CITATIONS
113	Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. <i>Diabetic Medicine</i> , 2014, 31, 1293-1300.	1.2	17
114	Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. <i>Journal of Diabetes Investigation</i> , 2014, 5, 320-326.	1.1	7
115	Achieving Glycemic Goals With Addition of Incretin-based Therapies to Insulin in Patients With Type 2 Diabetes Mellitus. <i>American Journal of the Medical Sciences</i> , 2014, 347, 491-501.	0.4	5
116	Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. <i>Postgraduate Medicine</i> , 2014, 126, 66-84.	0.9	10
117	Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes. <i>World Journal of Diabetes</i> , 2014, 5, 40.	1.3	46
118	Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 221-229.	1.0	27
119	Evaluation of add-on therapy of sitagliptin in Japanese patients with type 2 diabetes under insulin therapy. <i>Diabetology International</i> , 2014, 5, 187-197.	0.7	1
120	Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies. <i>Drugs and Aging</i> , 2014, 31, 203-214.	1.3	33
122	Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes. <i>Advances in Therapy</i> , 2014, 31, 289-317.	1.3	9
123	Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants. <i>Cardiovascular Therapeutics</i> , 2014, 32, 147-158.	1.1	111
124	Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 689-697.	1.1	167
125	Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. <i>Current Medical Research and Opinion</i> , 2014, 30, 431-445.	0.9	16
126	Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. <i>Drugs</i> , 2014, 74, 223-242.	4.9	79
127	Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands. <i>Clinical Drug Investigation</i> , 2014, 34, 135-146.	1.1	37
128	Add-On Treatment with Teneeligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 840-845.	2.4	25
129	Short- and long-term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients. <i>Journal of Diabetes Investigation</i> , 2014, 5, 548-553.	1.1	2
130	Composite endpoints in trials of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 492-499.	2.2	24
131	DPP-4 inhibitors: pharmacological differences and their clinical implications. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 57-68.	1.0	588



#	ARTICLE	IF	CITATIONS
133	Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 48-56.	2.2	83
134	Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. <i>Diabetes Care</i> , 2014, 37, 1815-1823.	4.3	311
135	Treating Patients With Diabetes of Long Duration: GLP-1 Receptor Agonists and Insulin in Combination. <i>Journal of Osteopathic Medicine</i> , 2014, 114, 22-29.	0.4	8
136	A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. <i>Saudi Pharmaceutical Journal</i> , 2014, 22, 403-410.	1.2	19
137	Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study. <i>Diabetes Research and Clinical Practice</i> , 2014, 103, e30-e33.	1.1	12
139	Meta-Analysis of the Cardiovascular Outcomes with Dipeptidyl Peptidase 4 Inhibitors: Validation of the Current FDA Mandate. <i>American Journal of Cardiovascular Drugs</i> , 2014, 14, 191-207.	1.0	14
140	Safety and efficacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion (CSII) therapy in patients with newly diagnosed type 2 diabetes. <i>Endocrine Journal</i> , 2014, 61, 513-521.	0.7	4
141	Implications of incretin-based therapies on cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2015, 69, 531-549.	0.8	11
142	Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control <i>via</i> different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. <i>Endocrine Journal</i> , 2015, 62, 133-143.	0.7	14
143	Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 936-948.	2.2	207
144	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan â€ 2015. <i>Endocrine Practice</i> , 2015, 21, 1-87.	1.1	443
145	Analyzing the Factors Contributing to Withdrawal from Insulin Therapy following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin. <i>Japanese Clinical Medicine</i> , 2015, 6, JCM.S27202.	1.9	0
146	The place of IDegLira in the management of patients with Type 2 diabetes. <i>Diabetes Management</i> , 2015, 5, 369-378.	0.5	0
147	Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes. <i>Journal of Clinical Medicine Research</i> , 2015, 7, 211-219.	0.6	14
148	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 1403-1414.	1.1	22
149	Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial. <i>PLoS ONE</i> , 2015, 10, e0121988.	1.1	26
150	Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	0.6	10
151	The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A â€œMe Tooâ€ or â€œthe Special Oneâ€-Antidiabetic Class?. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-28.	1.0	65

#	ARTICLE	IF	CITATIONS
152	New pharmacological approaches to diabetes management. <i>Practice Nursing</i> , 2015, 26, 140-146.	0.1	1
153	Fasting Versus Postprandial Hyperglycemia as a Treatment Target to Lower Elevated Hemoglobin A1C. <i>Endocrine Practice</i> , 2015, 21, 1323-1332.	1.1	7
154	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 638-652.	5.5	84
156	Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control. <i>Diabetes and Metabolism</i> , 2015, 41, 6S3-6S8.	1.4	5
157	Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial). <i>Primary Care Diabetes</i> , 2015, 9, 15-22.	0.9	16
158	Pharmacologic Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 540-556.	0.9	69
159	Efficacy of dipeptidyl peptidase-4 inhibitors and impact on $\beta$ -cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta-analysis. <i>Diabetes</i> , 2015, 7, 347-359.		
160	A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 831-838.	1.0	2
161	Sitagliptin for Type 2 diabetes: a 2015 update. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 597-610.	0.6	20
163	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. <i>Diabetes Therapy</i> , 2015, 6, 127-142.	1.2	37
164	Combination Therapy When Metformin Is Not an Option for Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2015, 49, 688-699.	0.9	7
166	Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2015, 127, 463-479.	0.9	11
167	Evidence-based practice guideline for the treatment for diabetes in Japan 2013. <i>Diabetology International</i> , 2015, 6, 151-187.	0.7	65
168	Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes. <i>The Diabetes Educator</i> , 2015, 41, 19S-31S.	2.6	5
169	Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial). <i>BMJ</i> , 2015, 351, h5364.	3.0	53
170	Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 339.	1.8	43
171	Practical combination therapy based on pathophysiology of type 2 diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2016, Volume 9, 355-369.	1.1	16
172	Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up. <i>Kosin Medical Journal</i> , 2016, 31, 146.	0.1	0

#	ARTICLE	IF	CITATIONS
173	Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-7.	1.0	8
174	Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2263-2270.	2.0	12
175	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm " 2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016, 22, 84-113.	1.1	405
176	Treatment Approach to Patients With Severe Insulin Resistance. <i>Clinical Diabetes</i> , 2016, 34, 97-104.	1.2	39
177	Des essais randomis�s contr�s aux �tudes observationnelles. Apports, limites et le�ons. R�flexions � propos de lâ�tude ODYSSEE. <i>Medicine Des Maladies Metaboliques</i> , 2016, 10, 732-740.	0.1	0
178	DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes " A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 288-298.	1.1	52
179	Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 86-95.	1.1	22
180	Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 171-182.	1.1	15
181	Triple therapy combinations for the treatment of type 2 diabetes " A network meta-analysis. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 149-158.	1.1	31
182	Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2016, 7, 309-320.	1.2	3
183	DPP� inhibitors and risk of infections: a meta� analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 391-404.	1.7	54
184	Adverse effects of incretin� based therapies on major cardiovascular and arrhythmia events: meta� analysis of randomized trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 843-857.	1.7	25
185	Role of incretin� based therapies and sodium� glucose co� transporter� inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira. <i>Diabetic Medicine</i> , 2016, 33, 864-876.	1.2	7
186	How much is too much? Outcomes in patients using high�dose insulin glargine. <i>International Journal of Clinical Practice</i> , 2016, 70, 56-65.	0.8	31
187	Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. <i>The Cochrane Library</i> , 2016, 9, CD006992.	1.5	32
188	NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. <i>Science Translational Medicine</i> , 2016, 8, 334ra51.	5.8	182
189	Chronic administration of ethanol leaf extract of <i>Moringa oleifera</i> Lam. (Moringaceae) may compromise glycaemic efficacy of Sitagliptin with no significant effect in retinopathy in a diabetic rat model. <i>Journal of Ethnopharmacology</i> , 2016, 194, 895-903.	2.0	18
190	Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis. <i>BMC Pharmacology &amp; Toxicology</i> , 2016, 17, 40.	1.0	5

#	ARTICLE	IF	CITATIONS
191	Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan. <i>Diabetology International</i> , 2016, 7, 188-198.	0.7	5
192	Dipeptidyl peptidase-4 inhibitors. , 2016, , 45-60.		0
193	Optimizing management of glycaemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 397-411.	2.2	10
194	Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE). <i>Diabetes Care</i> , 2016, 39, 455-464.	4.3	110
195	Incretin-Based Therapy for Diabetes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1488-1496.	1.2	32
196	Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. <i>Diabetology International</i> . 2016, 7, 299-307.	0.7	4
197	A systematic review of the safety of incretin-based therapies in type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 217-232.	1.2	4
198	Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. <i>Diabetologia</i> , 2016, 59, 907-917.	2.9	56
199	Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. <i>BMJ</i> , The, 2016, 352, i610.	3.0	183
200	New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. <i>Postgraduate Medical Journal</i> , 2016, 92, 152-164.	0.9	22
201	Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2016, 211, 88-95.	0.8	66
202	Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 605-616.	1.3	3
203	Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 409-418.	1.3	10
204	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. <i>Canadian Journal of Diabetes</i> , 2016, 40, 50-57.	0.4	27
205	Efficacy and safety of coadministration of sitagliptin with insulin glargine in type 2 diabetes. <i>Journal of Diabetes</i> , 2017, 9, 502-509.	0.8	8
206	Basal insulin treatment intensification in patients with type 2 diabetes mellitus: A comprehensive systematic review of current options. <i>Diabetes and Metabolism</i> , 2017, 43, 110-124.	1.4	9
207	Sitagliptin: A Review in Type 2 Diabetes. <i>Drugs</i> , 2017, 77, 209-224.	4.9	83
208	Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. <i>CMAJ Open</i> , 2017, 5, E152-E177.	1.1	57

#	ARTICLE	IF	CITATIONS
209	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary. <i>Endocrine Practice</i> , 2017, 23, 207-238.	1.1	362
210	Endothelial long non-coding RNAs regulated by oxidized LDL. <i>Molecular and Cellular Biochemistry</i> , 2017, 431, 139-149.	1.4	23
211	HbA 1c Outcomes in Patients Treated With Canagliflozin Versus Sitagliptin in US Health Plans. <i>Clinical Therapeutics</i> , 2017, 39, 2061-2072.	1.1	5
212	Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. <i>Clinical Therapeutics</i> , 2017, 39, 1780-1789.e33.	1.1	33
213	Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2017, 8, 321-329.	1.1	12
214	Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2818.	1.7	50
215	Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 143-155.	1.0	33
216	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. <i>Canadian Journal of Diabetes</i> , 2018, 42, S88-S103.	0.4	153
217	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Journal of Diabetes Investigation</i> , 2018, 9, 657-697.	1.1	158
218	Insulin Treatment. <i>Endocrinology</i> , 2018, , 1-24.	0.1	0
219	A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 34-46.	2.2	57
220	A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2064-2074.	2.2	0
221	Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis. <i>Scientific Reports</i> , 2018, 8, 4095.	1.6	14
222	Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 113-122.	1.2	29
223	Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2018, 126, 268-276.	0.6	4
224	Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis. <i>Journal of Diabetes Investigation</i> , 2018, 9, 813-821.	1.1	19
225	Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1044-1049.	2.2	9
226	DPP-4 Inhibitors and Fat Metabolism in Patients with Type 2 Diabetes. , 0, , .		1

#	ARTICLE	IF	CITATIONS
227	Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 75.	1.2	5
228	Baseline Glycated Hemoglobin Values Predict the Magnitude of Glycemic Improvement in Patients with Type 1 and Type 2 Diabetes: Subgroup Analyses from the DIAMOND Study Program. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 561-565.	2.4	28
229	Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials. <i>Diabetes Therapy</i> , 2018, 9, 1581-1589.	1.2	3
230	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
231	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Diabetology International</i> , 2018, 9, 1-45.	0.7	215
232	Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios. <i>Diabetes Therapy</i> , 2018, 9, 1775-1789.	1.2	43
233	Current Antidiabetic Drugs. , 2018, , 455-473.		17
234	DPP-4 Inhibition and the Path to Clinical Proof. <i>Frontiers in Endocrinology</i> , 2019, 10, 376.	1.5	68
235	Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus. <i>Bioscience Reports</i> , 2019, 39, .	1.1	4
236	<p>Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 1513-1526.	1.1	10
237	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes: A Network Meta-analysis. <i>SSRN Electronic Journal</i> , 2019, , .	0.4	0
238	Post-marketing Study of Linagliptin: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 576.	1.6	2
239	Intensive monitoring for post-transplant diabetes mellitus and treatment with dipeptidyl peptidase-4 inhibitor therapy. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 1857-1863.	1.8	6
240	Progression of glucose-lowering diabetes therapy in TECOS. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00053.	1.0	7
241	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	1.1	245
242	Meal-time + basal insulin therapy: Is all not well?. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107923.	1.1	0
243	Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 408-411.	2.2	2
244	Cost-effectiveness of intensification with sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1010-1017.	2.2	7

#	ARTICLE	IF	CITATIONS
245	Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT Study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 781-790.	2.2	19
246	All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes. <i>BMC Endocrine Disorders</i> , 2019, 19, 3.	0.9	6
247	Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 123-127.	2.2	5
248	Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. <i>BMC Medicine</i> , 2020, 18, 322.	2.3	5
249	Meta-Analysis of 11 Heterogeneous Studies regarding Dipeptidyl Peptidase 4 Inhibitor Add-On Therapy for Type 2 Diabetes Mellitus Patients Treated with Insulin. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-12.	1.0	5
250	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1020-1076.	1.1	159
251	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020, 11, 165-223.	0.7	266
252	PERsistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001507.	1.2	0
253	Effect of Dipeptidyl Peptidase-4 Inhibitors Used in Combination with Insulin Treatment in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis. <i>Diabetes Therapy</i> , 2020, 11, 2371-2382.	1.2	2
254	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
255	Random-effects meta-analysis of combined outcomes based on reconstructions of individual patient data. <i>Research Synthesis Methods</i> , 2020, 11, 594-616.	4.2	4
256	Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. <i>Diabetes/Metabolism Research and Reviews</i> , 2021, 37, e3391.	1.7	13
257	Efficacy and safety of DPP-4 inhibitors combined with basal insulin in the treatment of type 2 diabetes. <i>Journal of Diabetes</i> , 2021, 13, 375-389.	0.8	1
258	Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2). <i>Advances in Therapy</i> , 2021, 38, 1514-1535.	1.3	1
259	A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1242-1251.	2.2	4
260	Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153502.	1.1	6
261	The effect of concomitant DPP-4 inhibitor use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. <i>PLoS ONE</i> , 2018, 13, e0190579.	1.1	2
262	Detemir (Levemir): modern paradigms of insulin therapy. <i>Problemy Endokrinologii</i> , 2013, 59, 56-64.	0.2	4

#	ARTICLE	IF	CITATIONS
263	Comparative Efficiency of Sulfonylurea and/or Dipeptidyl Peptidase-4 inhibitor in Basal-Supported Oral Therapy in Japanese Patients with Type 2 Diabetes (JDDM39). <i>Journal of Diabetes and Obesity</i> , 2015, 2, 1-6.	0.2	1
264	The Role of Incretin Therapy at Different Stages of Diabetes. <i>Review of Diabetic Studies</i> , 2011, 8, 323-338.	0.5	22
265	Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 432.	1.8	2
266	Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 32.	0.2	4
267	Safety and Efficacy of Combination Therapy with Insulin Glargine and Oral Hypoglycaemic Agents Including DPP-4 Inhibitors in Japanese T2DM Patients: ALOHA 2 Study, a Post-Marketing Surveillance for Lantus&lt;sup&gt;&reg;&lt;/sup&gt;. <i>Journal of Diabetes Mellitus</i> , 2014, 04, 273-289.	0.1	11
268	Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. <i>World Journal of Diabetes</i> , 2013, 4, 151.	1.3	13
270	Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2015, 9, FC07-10.	0.8	2
271	EVIDENCE BASE OF SITAGLIPTIN CLINICAL USE. 10 YEARS IN THE MARKET OF THE WORLD. <i>Problemi Endokrinnoi Patologii</i> , 2016, 56, 74-79.	0.0	0
272	Insulin Treatment. <i>Endocrinology</i> , 2018, , 617-640.	0.1	1
273	Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus. <i>P and T</i> , 2012, 37, 699-708.	1.0	8
274	Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 14141-50.	0.5	15
275	Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. <i>Pediatric Diabetes</i> , 2022, 23, 183-193.	1.2	14
276	A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. <i>Pediatric Diabetes</i> , 2022, 23, 173-182.	1.2	13
277	Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 324-331.	2.4	5
278	Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 0, , e068882.	3.0	13
279	Impact of the Fasting Plasma Glucose Titration Target on the Success of Basal Insulin Titration in Insulin-Naïve Patients with Type 2 Diabetes: A Systematic Analysis. <i>Journal of Diabetes Research</i> , 2022, 2022, 1-12.	1.0	0
280	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€™2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
281	Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study. <i>Scientific Reports</i> , 2023, 13, .	1.6	4



#	ARTICLE	IF	CITATIONS
282	Structural characterization, $\alpha$ -glucosidase inhibitory activity and antioxidant activity of neutral polysaccharide from apricot ( <i>Armeniaca Sibirica</i> L. Lam) kernels. <i>International Journal of Biological Macromolecules</i> , 2023, 238, 124109.	3.6	10
284	Treatment Approaches and Challenges. , 2023, , 31-56.		0